Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: The shift after United States food and drug administration policy changes

Pharmacotherapy

Volumn 32, Issue 11, 2012, Pages 988-997

  Stroupe, Kevin T ^a,b,c,d   Tarlov, Elizabeth ^a,b   Lee, Todd A ^a,e   Weichle, Thomas W ^a   Zhang, Qiuying L ^a   Michaelis, Laura C ^c,d   Ozer, Howard ^f   Durazo Arvizu, Ramon ^c,d   Browning, Margaret M ^a,b   Hynes, Denise M ^a,b,e,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Veterans Affairs Information Resource Center   (United States)

^c HINES VA HOSPITAL   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Anemia; Chemotherapy; Erythropoiesis stimulating agents; ESA; Hemoglobin

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AFRICAN AMERICAN; AGED; ANEMIA; ARTICLE; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER STAGING; COHORT ANALYSIS; COLON CANCER; DRUG LEGISLATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OROPHARYNX CANCER; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; UROGENITAL TRACT CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COHORT STUDIES; DRUG LABELING; ELECTRONIC HEALTH RECORDS; FEMALE; HEMATINICS; HEMOGLOBINS; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PUBLIC POLICY; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84871581983     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1134     Document Type: Article

References (35)

1. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol 2011;125(1-2):55-67
2. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11(13):1-iv
3. Fatodu H. Evolving regulatory landscape with erythropoiesisstimulating agents and impact on managed care. Am J Manag Care 2010;16:S74-9
4. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373 (9674):1532-42
5. U.S. Department of Health & Human Services, U.S. Food and Drug Administration. Drugs@FDA. Available from http://www accessdata.fda.gov/scripts/ cder/drugsatfda. Accessed November 10, 2011
6. Henke M, Laszig R, Rube C, et al. Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2003;362:1255-60
7. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459-60 (Pubitemid 37009952)
8. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26(1):132-49
9. Phurrough S, Jacques L, Ciccanti M, et al. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). U.S. Department of Health & Human Services, Centers for Medicare and Medicaid Services; 2007 Jul 30. Available from http://www.cms.gov/ medicare-coverage-database/indexes/nca-open-and-closed-index.aspx. Accessed November 10, 2011
10. Wright JD, Neugut AI, Wilde ET, et al. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 2011;29 (25):3408-18
11. Tarlov E, Stroupe KT, Lee TA, et al. Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. Support Care Cancer 2012;20(8):1649-57
12. Polsky D, Eremina D, Hess G, et al. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy- induced anaemia. Pharmacoeconomics 2009;27 (9):755-65
13. Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002
14. Commission on Cancer. Facility oncology registry data standards (FORDS). American College of Surgeons; 2002
15. VA Information Resource Center. VIReC research user guide: FY2006 VHA medical SAS® inpatient datasets. Edward J Hines, Jr. VA Hospital, Hines, IL: U.S. Department of Veterans Affairs, VA Information Resource Center, 2007
16. VA Information Resource Center. VIReC research user guide FY2006 VHA medical SAS® outpatient datasets. Edward J Hines, Jr. VA Hospital, Hines, IL: U.S. Department of Veterans Affairs, VA Information Resource Center, 2007
17. VA Information Resource Center. VIReC research user guide VHA pharmacy prescription data, 2nd ed. Edward J. Hines, Jr VA Hospital, Hines, IL: U.S. Department of Veterans Affairs, VA Information Resource Center, 2009
18. Sohn MW, Zhang H, Arnold N, et al. Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. Popul Health Metr 2006;4:7
19. Stroupe KT, Tarlov E, Zhang Q, Haywood T, Owens A, Hynes D. Use of Medicare and DOD data for improving VA race data quality. J Rehabil Res Dev 2010;47(8):781-95
20. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53(12):1258-67 (Pubitemid 32007842)
21. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006;44 (10):921-8 (Pubitemid 44454569)
22. Cochrane LJ, Olson CA, Murray S, Dupuis M, Tooman T, Hayes S. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. J Contin Educ Health Prof 2007;27(2):94-102
23. Pritchard RS, Fisher ES, Teno JM, et al. Influence of patient preferences and local health system characteristics on the place of death. SUPPORT investigators. Study to understand prognoses and preferences for risks and outcomes of treatment J Am Geriatr Soc 1998;46(10):1242-50
24. Sirovich BE, Gottlieb DJ, Welch HG, Fisher ES. Regional variations in health care intensity and physician perceptions of quality of care. Ann Intern Med 2006;144(9):641-9 (Pubitemid 46780648)
25. StataCorp LP. STATA statistical software, release 12.1, STATA MP system for Windows. College Station, TX: StataCorp LP, 2011
26. Pollack A. Drug company halts trials of Procrit. New York Times. November 27, 2003
27. Pollack A. FDA Wants more study on 2 drugs for anemia New York Times. May 4, 2004
28. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98 (10):708-14 (Pubitemid 43821788)
29. Hess G, Hill J, Clough J, Hulnick S, Nordyke RJ. Utilization of darbepoetin alfa in relation to cancer patients hemoglobin levels. Curr Med Res Opin 2008;24(3):815-9 (Pubitemid 351428993)
30. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 2011;117(14):3268-75
31. Vadhan-Raj S, Zhou X, Sizer K, et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesisstimulating agents and RBC transfusions. Oncologist 2010;15:1359-69
32. Lal LS, Raju A, Miller LA, Chen H, Arbuckle R, Sansgiry SS Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients. Support Care Cancer 2010;19(2):251-9
33. Steinmetz T, Totzke U, Söling U, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia - examination of practice in Germany. Curr Med Res Opin 2008;24(10):2751-6
34. Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. J Manag Care Pharm 2008;14(9):858-69
35. Juneja V, Keegan P, Gootenberg JE, et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 2008;14:3242-7